Osteochondrodysplasias: Clinical Trials

37 trials for Osteochondrodysplasias, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

19 completed, 8 terminated, 4 active not recruiting, 2 not yet recruiting. 37 Phase 1, 12 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 137Completed 19, Terminated 8, Active not recruiting 4, Not yet recruiting 2, Recruiting 2, Unknown 1, Withdrawn 1
Phase 212Terminated 3, Active not recruiting 2, Completed 2, Not yet recruiting 2, Recruiting 1, Unknown 1, Withdrawn 1

Follow Osteochondrodysplasias: new trials by email Literature Review of Osteochondrodysplasias trials Research Report on Osteochondrodysplasias

Trials (filtered) newest first · largest first

All 37 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI)
Bone marrow-derived mesenchymal stromal cells (MSCs) - Osteogenesis Imperfecta, Osteogenesis Imperfecta Type III
Phase 1 / Phase 2Not yet recruitingEmory University122027-01-012026-05-08
Gene-Modified Stem Cell Therapy for Children With Autosomal Recessive Osteopetrosis (ARO)
FT024 - Osteopetrosis
Phase 1 / Phase 2RecruitingFondazione Telethon82026-06-202026-06-24
A Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondroplasia
ABSK061 - Achondroplasia
Phase 1 / Phase 2Not yet recruitingAbbisko Therapeutics Co, Ltd1102025-12-102025-12-22
An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
HCB301 - Advanced Solid Tumor, Refractory Hodgkin Lymphoma
Phase 1RecruitingFBD Biologics Limited502025-04-022026-04-13
Metformin Repurposing in Oral Submucous Fibrosis: Unveiling In Vitro Signaling Pathways, Progressing to Clinical Trial
Metformin Hydrochloride, betamethasone dipropionate, Pentoxifylline - Oral Submucous Fibrosis
Phase 1 / Phase 2CompletedZiauddin University302024-08-122025-05-02
A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers
AGA2115, Placebo - Osteogenesis Imperfecta
Phase 1CompletedAngitia Incorporated Limited722023-10-032025-01-10
A First-in-Human Phase 1 Study of Plasmalogen Precursor PPI-1011 in Healthy Adult Volunteers to Assess Safety, Tolerability, and Pharmacokinetics
PPI-1011, Placebo - Rhizomelic Chondrodysplasia Punctata
Phase 1CompletedMED-LIFE DISCOVERIES LP562023-06-282026-10-09
Bioequivalence Study to Compare Two Injection Devices for BMN 111 in Healthy Participants
BMN 111 administration via Injector Pen, BMN 111 administration via vial and syringe - Achondroplasia
Phase 1TerminatedBioMarin Pharmaceutical362023-03-152023-10-12
Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)
SAR439459, Placebo - Osteogenesis Imperfecta
Phase 1TerminatedSanofi162022-08-252025-09-11
Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors
TST005 - Locally Advanced or Metastatic Cancers, Metastatic Human Papillomavirus-Related Malignant Neoplasm
Phase 1TerminatedTranscenta Therapeutics (Hangzhou) Co., Ltd.192021-06-112023-10-23
Study to Evaluate Romosozumab in Children and Adolescents With Osteogenesis Imperfecta
Romosozumab, Calcium, Vitamin D - Osteogenesis Imperfecta
Phase 1CompletedAmgen252021-01-212024-04-15
A First-in-human Single and Repeated Dose Escalation Study of SAR442501 in Healthy Adults Subjects
SAR442501, Placebo - Osteochondrodysplasia
Phase 1CompletedSanofi762020-11-182024-08-27
Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)
M7824, Carboplatin, Paclitaxel - Cervical Cancer
Phase 1CompletedEMD Serono Research & Development Institute, Inc.252020-10-192024-03-08
Losartan to Improve Hip Microfracture
Losartan, Placebo - Hip Osteoarthritis, Hip Impingement Syndrome
Phase 1 / Phase 2TerminatedSteadman Philippon Research Institute12020-08-072023-10-30
Bioimaging Study of 89Zr-M7824 in NSCLC
89Zirconium-M7824, M7824 - Non-Small Cell Lung Cancer
Phase 1 / Phase 2TerminatedOlivia Newton-John Cancer Research Institute52020-06-012023-01-17
A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer
LY3200882, Pembrolizumab - Advanced Cancer
Phase 1 / Phase 2WithdrawnEli Lilly and Company2019-12-052020-02-19
Boost Brittle Bones Before Birth
BOOST cells - Osteogenesis Imperfecta
Phase 1 / Phase 2Active not recruitingKarolinska Institutet182019-08-122025-09-12
Boost to Brittle Bones - Stem Cell Transplantation for Treatment of Brittle Bones
BOOST cells - Osteogenesis Imperfecta
Phase 1 / Phase 2UnknownChristian Medical College, Vellore, India152019-05-202020-11-10
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
PF-06952229, Enzalutamide - Breast Neoplasms, Prostate Neoplasms
Phase 1TerminatedPfizer492018-10-042024-06-26
Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta
Fresolimumab - Osteogenesis Imperfecta
Phase 1CompletedBaylor College of Medicine112017-11-152024-12-04

Showing 20 of 37. Sign in to see all of them.

Narrower conditions

Camurati-Engelmann Syndrome (14)  ·  Osteogenesis Imperfecta (11)  ·  Osteopetrosis (5)  ·  Achondroplasia (3)  ·  Neoplasms (3)  ·  Anemia (2)  ·  Anemia, Aplastic (2)  ·  Anemia, Sickle Cell (2)  ·  Breast Neoplasms (2)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Cytopenia (2)  ·  Hematologic Neoplasms (2)  ·  Leukemia (2)  ·  Leukemia, Myeloid, Acute (2)  ·  Lymphoma, Non-Hodgkin (2)

Broader conditions

Bone Diseases (37)  ·  Bone Diseases, Developmental (37)  ·  Musculoskeletal Diseases (37)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (33)  ·  Genetic Diseases, Inborn (32)  ·  Skin and Connective Tissue Diseases (14)  ·  Connective Tissue Diseases (12)  ·  Collagen Diseases (11)  ·  Neoplasms (8)  ·  Neoplasms by Site (8)  ·  Neoplasms by Histologic Type (6)  ·  Immune System Diseases (5)  ·  Metabolic Diseases (5)  ·  Nutritional and Metabolic Diseases (5)

Interventions

AP 1903 reagent (2)  ·  Cisplatin (2)  ·  Cyclophosphamide (2)  ·  bintrafusp alfa protein, human (2)  ·  130-nm albumin-bound paclitaxel (1)  ·  Betamethasone Valerate (1)  ·  Bevacizumab (1)  ·  Bone Marrow Transplantation (1)  ·  Busulfan (1)  ·  Calcium (1)  ·  Carboplatin (1)  ·  Cyclosporine (1)  ·  Fenretinide (1)  ·  Gemcitabine (1)  ·  Hematopoietic Stem Cell Transplantation (1)

Sponsors

Baylor College of Medicine (3)  ·  Bellicum Pharmaceuticals (2)  ·  BioMarin Pharmaceutical (2)  ·  Eli Lilly and Company (2)  ·  Sanofi (2)  ·  St. Jude Children's Research Hospital (2)  ·  Abbisko Therapeutics Co, Ltd (1)  ·  Amgen (1)  ·  Angitia Incorporated Limited (1)  ·  Children's Hospital Los Angeles (1)  ·  Christian Medical College, Vellore, India (1)  ·  EMD Serono Research & Development Institute, Inc. (1)  ·  Emory University (1)  ·  FBD Biologics Limited (1)  ·  Fondazione Telethon (1)

Countries

United States (26)  ·  Spain (5)  ·  Italy (4)  ·  Australia (3)  ·  Canada (3)  ·  France (3)  ·  China (2)  ·  Germany (2)  ·  Japan (2)  ·  Austria (1)  ·  Greece (1)  ·  Hungary (1)  ·  India (1)  ·  Pakistan (1)  ·  Sweden (1)

Top investigators

Kimberly Kasow, DO (2)  ·  Alix Seif, MD (1)  ·  Andrew M Scott, MBBS (1)  ·  Brendan Lee, M.D., Ph.D. (1)  ·  Charlie Qi, MD (1)  ·  Chen Li, Master (1)  ·  Doris Fadoju, MD (1)  ·  Helen Heslop, MD (1)  ·  Hisham Abdel-Azim, MD (1)

Results publications

PMID 28390753, PMID 31472446, PMID 33008091, PMID 34007848, PMID 34548321, PMID 35113812, PMID 35223854, PMID 35410255, PMID 36552855, PMID 38261781, PMID 38834319, PMID 39214047, PMID 42470570

NIH funding

2015 (1), 2016 (1), 2017 (1), 2019 (1), P01CA094237 (1)